

## **SWISS IBD COHORT PUBLICATION LIST**

### **2016**

Alatri A, Schoepfer A, Fournier N, Engelberger RP, Safroneeva E, Vavricka S, Biedermann L, Calanca L, Mazzolai L; Swiss IBD Cohort Study Group. *Prevalence and risk factors for venous thromboembolic complications in the Swiss Inflammatory Bowel Disease Cohort.* [Scand J Gastroenterol.](#) 2016 Oct;51(10):1200-5.

Duchatellier CF, Kumar R, Krupoves A, Braegger C, Herzog D, Amre DK. *Steroid Administration and Growth Impairment in Children with Crohn's Disease.* [Inflamm Bowel Dis.](#) 2016 Feb;22(2):355-63.

Fraga M, Fournier N, Safroneeva E, Pittet V, Godat S, Straumann A, Nydegger A, Vavricka S, R, Moradpour D, Schoepfer A, M, and the Swiss IBD Cohort Study Group. *Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.* [Eur J Gastroenterol Hepatol.](#) 2017 Jan;29(1):91-97.

Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Rogler G, Safroneeva E, Ali RA, Braegger C, Heyland K, Mueller P, Nydegger A, Petit LM, Schibli S, Furlano RI, Spalinger J, Schäppi M, Zamora S, Froehlich F, Herzog D, Schoepfer AM, Vavricka SR; Swiss IBD Cohort Study Group. *Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation and anti-TNF Treatment.* [J Pediatr Gastroenterol Nutr.](#) 2016 Oct 31. [Epub ahead of print]

Kasper SH, Spalinger MR, Leonardi I, Gerstgrasser A, Raselli T, Gottier C, Atrott K, Frey-Wagner I, Fischbeck-Terhalle A, Rogler G, Scharl M. *Deficiency of Protein Tyrosine Phosphatase Non-Receptor Type 2 in Intestinal Epithelial Cells Has No Appreciable Impact on Dextran Sulphate Sodium Colitis Severity But Promotes Wound Healing.* [Digestion.](#) 2016;93(4):249-59.

Madanchi M, Zeitz J, Barthel C, Samaras P, Scharl S, Sulz MC, Biedermann L, Frei P, Vavricka SR, Rogler G, Scharl M. *Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience.* [Digestion.](#) 2016;94(1):1-8.

Manser CN, Borovicka J, Seibold F, Vavricka SR, Lakatos PL, Fried M, Rogler G; investigators of the Swiss Inflammatory Bowel Disease Cohort Study. *Risk factors for complications in patients with ulcerative colitis.* [United European Gastroenterol J.](#) 2016 Apr;4(2):281-7.

Mikocka-Walus A, Pittet V, Rossel JB, von Känel R. *Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease.* [Clin Gastroenterol Hepatol.](#) 2016 Jun;14(6):829-835.

Mueller R, Ziade F, Pittet V, Fournier N, Ezri J, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A; and the Swiss IBD Cohort Study. *Quality of Life in Swiss Paediatric Inflammatory Bowel Disease Patients : Do Patients and Their Parents Experience Disease in the Same Way?* [J Crohns Colitis.](#) 2016 Mar;10(3):269-76.

Pittet V, Vaucher C, Maillard MH, Girardin M, de Saussure P, Burnand B, Rogler G, Michetti P. *Information Needs and Concerns of Patients with Inflammatory Bowel Disease: What Can We Learn from Participants in a Bilingual Clinical Cohort?* [PLoS One.](#) 2016 Mar 3;11(3):e0150620. doi: 10.1371.

Protic M, Schoepfer A, Yawalkar N, Vavricka S, Seibold F. *Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.* [Scand J Gastroenterol.](#) 2016 Dec;51(12):1482-1488.

Rau M, Stieger B, Monte MJ, Schmitt J, Jahn D, Frey-Wagner I, Raselli T, Marin JJ, Müllhaupt B, Rogler G, Geier A. *Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation.* 2016 Oct;22(10):2382-9.

Rieder F, Fiocchi C, Rogler G. *Mechanisms, Management, and Treatment of Fibrosis in Patients with Inflammatory Bowel Diseases.* [Gastroenterology.](#) 2016 Oct 5. pii: S0016-5085(16)35172-1. doi: 10.1053.

Roth S, Spalinger MR, Gottier C, Biedermann L, Zeitz J, Lang S, Weber A, Rogler G, Scharl M. *Bilberry-Derived Anthocyanins Modulate Cytokine Expression in the Intestine of Patients with Ulcerative Colitis.* [PLoS One.](#) 2016 May 6;11(5):e0154817. doi: 10.1371.

Rogler G, Zeitz J, Biedermann L. *The Search for Causative Environmental Factors in Inflammatory Bowel Disease.* [Dig Dis.](#) 2016;34 Suppl 1:48-55. doi: 10.1159.

Ruiz PA, Morón B, Becker HM, Lang S, Atrott K, Spalinger MR, Scharl M, Wojtal KA, Fischbeck-Terhalle A, Frey-Wagner I, Hausmann M, Kraemer T, Rogler G. *Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome.* [Gut.](#) 2016 Feb 4. pii: gutjnl-2015-310297. doi: 10.1136.

Scharl M, Bruckner RS, Rogler G. *The two sides of the coin: Similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel disease.* [United European Gastroenterol J.](#) 2016 Aug;4(4):506-14.

Schoepfer AM, Vavricka S, Safroneeva E, Fournier N, Manser C, Frei P, Deltenre P, Rogler G, Straumann A, Ezri J, Nydegger A, Braegger C. *Systematic Evaluation of Diagnostic Delay in Pediatric Inflammatory Bowel Disease.* [J Pediatr Gastroenterol Nutr.](#) 2016 Apr 18. [Epub ahead of print]

Schüle S, Rossel JB, Frey D, Biedermann L, Scharl M, Zeitz J, Freitas-Queiroz N, Pittet V, Vavricka SR, Rogler G, Misselwitz B; Swiss IBD cohort study. *Prediction of low bone mineral density in patients with inflammatory bowel diseases.* [United European Gastroenterol J.](#) 2016 Oct;4(5):669-676.

Smolinska Sylwia, Groeger David, Rodriguez Perez Noelia, Schiavi Elisa, Ferstl Ruth, Frei Remo, Konieczna Patrycja, Akdis Cezmi A., Jutel Marek and O'Mahony Liam. *Histamine Receptor 2 is Required to Suppress Innate Immune Responses to Bacterial Ligands in Patients with Inflammatory Bowel Disease.* [Inflamm Bowel Dis.](#) 2016 Jul;22(7):1575-86. doi: 10.1097.

Spalinger MR, Zeitz J, Biedermann L, Rossel JB, Sulz MC, Frei P, Scharl S, Vavricka SR, Fried M, Rogler G, Scharl M; Swiss IBD Cohort Study Group. *Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort.* [PLoS One.](#) 2016 Jul 28;11(7):e0160215. doi: 10.1371.

Spalinger MR, Kasper S, Gottier C, Lang S, Atrott K, Vavricka SR, Scharl S, Gutte PM, Grütter MG, Beer HD, Contassot E, Chan AC, Dai X, Rawlings DJ, Mair F, Becher B, Falk W, Fried M, Rogler G, Scharl M. *NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22.* [J Clin Invest.](#) 2016 May 2;126(5):1783-800. doi: 10.1172.

Spalinger MR, Voegelin M, Biedermann L, Zeitz J, Rossel JB, Sulz MC, Frei P, Scharl S, Vavricka SR, Fried M, Rogler G, Scharl M; Swiss IBD Cohort Study Group. *The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort.* [Digestion.](#) 2016 Feb 27;93(3):182-192.

Vaucher C, Maillard MH, Froehlich F, Burnand B, Michetti P, Pittet V. *Patients and gastroenterologists' perceptions of treatments for inflammatory bowel diseases: do their perspectives match?* [Scand J Gastroenterol.](#) 2016 Feb 19:1-6.

Vögelin M, Biedermann L, Frei P, Vavricka SR, Scharl S, Zeitz J, Sulz MC, Fried M, Rogler G, Scharl M. *The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease.* [PLoS One.](#) 2016 May 23;11(5):e0155218. doi: 10.1371

Zeitz J, Bissig M, Barthel C, Biedermann L, Scharl S, Pohl D, Frei P, Vavricka SR, Fried M, Rogler G, Scharl M. *Patients' views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease?* [Eur J Gastroenterol Hepatol.](#) 2016 Nov 22. [Epub ahead of print]

Zeitz J, Ak M, Müller-Mottet S, Scharl S, Biedermann L, Fournier N, Frei P, Pittet V, Scharl M, Fried M, Rogler G, Vavricka S, Swiss IBD Cohort Study Group. *Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account.* [PLoS One.](#) 2016 Jun 22;11(6):e0156666. doi: 10.1371.

## 2015

Biedermann L, Fournier N, Misselwitz B, Frei P, Zeitz J, Manser CN, Pittet V, Juillerat P, von Känel R, Fried M, Vavricka S, Rogler G, ; Swiss Inflammatory Bowel Disease Cohort Study Group. *High rates of smoking especially in female Crohn's disease patients and low use of supportive measures to achieve smoking cessation - Data from the SwissIBD cohort study.* [J Crohns Colitis.](#) 2015 Oct;9(10):819-29.

Burkhalter H, Stucki-Thür P, David P, Lorenz S, Biotti B, Rogler G, Pittet V. *Assessment of Inflammatory Bowel Disease Patient's Needs and Problems from a Nursing Perspective.* [Digestion.](#) 2015;91(2):128-41.

De Vallière C, Vidal S, Clay I, Jurisic G, Tcymbarevich I, Lang S, Ludwig MG, Okoniewski M, Eloranta JJ, Kullak-Ublick GA, Wagner CA, Rogler G, Seuwen K. *The pH-Sensing Receptor OGR1 Improves Barrier Function of Epithelial Cells and Inhibits Migration in an Acidic Environment.* [Am J Physiol Gastrointest Liver Physiol.](#) 2015 Sep 15;309(6):G475-90.

De Vallière C, Wang Y, Eloranta JJ, Vidal S, Clay I, Spalinger MR, Tcymbarevich I, Terhalle A, Ludwig MG, Suply T, Fried M, Kullak-Ublick GA, Frey-Wagner I, Scharl M, Seuwen K, Wagner CA, Rogler G. *G Protein-coupled pH-sensing Receptor OGR1 Is a Regulator of Intestinal Inflammation*. [Inflamm Bowel Dis](#). 2015 Jun;21(6):1269-81.

Ditisheim S, Fournier N, Juillerat P, Pittet V, Michetti P, Gabay C, Finckh A. *Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort Study*. [Inflamm Bowel Dis](#). 2015 Nov;21(11):2598-604.

Greuter T, Lang S, Holler E, Hawkey CJ, Rogler G, Biedermann L; ASTIC trial group. *Serum REG3alpha and C-Reactive Protein Levels in Crohn's Disease Patients Undergoing Immunoablation and Autologous Hemopoietic Stem Cell Transplantation in the ASTIC Trial*. [Digestion](#). 2015;92(2):83-9.

Juillerat P, Sokol H, Froehlich F, Yajnik V, Beaugerie L, Lucci M, Burnand B, Macpherson AJ, Cosnes J, Korzenik JR. *Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort*. [Inflamm Bowel Dis](#). 2015 Jan;21(1):60-70.

Leonardi I, Frey I, Rogler G. *Helminth therapy for organic diseases?* [Transl Res](#). 2015 Dec;166(6):586-601.

Multone E, Vader JP, Mottet C, Schoepfer A, Fournier N, Burnand B, Michetti P, Pittet V. *Characteristics of non-responders to self-reported questionnaires in a large inflammatory bowel disease cohort study*. [Scand J Gastroenterol](#). 2015;50(11):1348-56.

Pittet V, Maillard MH, Lauvergeon S, Timmer M, Michetti P, Froehlich F, Burnand B, Vader JP, Mottet C. *Acceptance of inflammatory bowel disease treatment recommendations based on appropriateness ratings: do practicing gastroenterologists agree with experts?* [J Crohns Colitis](#). 2015 Feb;9(2):132-9.

Rogler G. *Where are we heading to in pharmacological IBD therapy?* [Pharmacol Res](#). 2015 Oct;100:220-7.

Rogler G, Vavricka SR, Biedermann L. *Integrating Imaging into Clinical Practice in Inflammatory Bowel Disease*. [Dig Dis](#). 2015 Sep 14;33 Suppl 1:37-43.

Rogler G, Vavricka S. *Exposome in IBD: Recent Insights in Environmental Factors that Influence the Onset and Course of IBD*. [Inflamm Bowel Dis](#). 2015 Feb;21(2):400-8.

Rogler G, Vavricka S. *Anemia in inflammatory bowel disease: an under-estimated problem?* [Front Med \(Lausanne\)](#). 2015 Jan 19;1:58.

Safroneeva E, Vavricka SR, Fournier N, Straumann A, Rogler G, Schoepfer AM. *Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study*. [Inflamm Bowel Dis](#). 2015 Jun;21(6):1348-58.

Safroneeva E, Vavricka S, Fournier N, Seibold F, Mottet C, Nydegger A, Ezri J, Straumann A, Rogler G, Schoepfer AM; Swiss IBD Cohort Study Group. *Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients*. [Aliment Pharmacol Ther](#). 2015 Sep;42(5):540-8.

Safroneeva E, Vavricka SR, Fournier N, Pittet V, Peyrin-Biroulet L, Straumann A, Rogler G, Schoepfer AM; Swiss IBD Cohort Study Group. *Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease*. [Aliment Pharmacol Ther](#). 2015 Oct;42(8):977-89.

Scharl M, Huber N, Lang S, Fürst A, Jehle E, Rogler G. *Hallmarks of epithelial to mesenchymal transition are detectable in Crohn's disease associated intestinal fibrosis*. [Clin Transl Med](#). 2015 Feb 7;4:1.

Schoepfer A, Vavricka S. *The "Red Flag Instrument" for early Detection of Crohn's Disease: is it ready for Clinical Practice?* [J Crohns Colitis](#). 2015 Aug;9(8):597-8.

Spalinger MR, Kasper S, Chassard C, Raselli T, Frey-Wagner I, Gottier C, Lang S, Atrott K, Vavricka SR, Mair F, Becher B, Lacroix C, Fried M, Rogler G, Scharl M. *PTPN2 controls differentiation of CD4+ T cells and limits intestinal inflammation and intestinal dysbiosis*. [Mucosal Immunol](#). 2015 Jul;8(4):918-29.

Spalinger MR, McCole DF, Rogler G, Scharl M. *Role of Protein Tyrosine Phosphatases in Regulating the Immune System: Implications for Chronic Intestinal Inflammation*. [Inflamm Bowel Dis](#). 2015 Mar;21(3):645-55.

Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, Navarini AA, French LE, Safroneeva E, Fournier N, Straumann A, Froehlich F, Fried M, Michetti P, Seibold F, Lakatos PL, Peyrin-Biroulet L, Schoepfer AM. *Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.* [Inflamm Bowel Dis.](#) 2015 Aug;21(8):1794-800.

Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. *Extraintestinal Manifestations of Inflammatory Bowel Disease.* [Inflamm Bowel Dis.](#) 2015 Aug;21(8):1982-92.

Werner H, Braegger C, Buehr P, Koller R, Nydegger A, Spalinger J, Heyland K, Schibli S, Landolt M; Swiss IBD Cohort Study Group. *Shorter time since inflammatory bowel disease diagnosis in children is associated with lower mental health in parents.* *Acta Paediatr.* 2015 Jan;104(1):e32-8.

Zimmermann Kathrin, Sonia Bastidas, Leandra Knecht, Herbert Kuster, Stephan R. Vavricka, Huldrych F. Günthard, and Annette Oxenius. *Gut commensal microbes do not represent a dominant antigenic source for continuous CD4+ T-cell activation during HIV-1 infection.* [Eur J Immunol.](#) 2015 Nov;45(11):3107-13.

## 2014

Barthel C, Biedermann L, Frei P, Vavricka SR, Kündig T, Fried M, Rogler G, Scharl M. *Induction or Exacerbation of Psoriasis in Patients with Crohn's Disease under Treatment with Anti-TNF Antibodies.* [Digestion.](#) 2014;89(3):209-15.

Biedermann L, Brülisauer K, Zeitz J, Frei P, Scharl M, Vavricka SR, Fried M, Loessner MJ, Rogler G, Schuppler M. *Smoking Cessation Alters Intestinal Microbiota: Insights from Quantitative Investigations on Human Fecal Samples Using FISH.* [Inflamm Bowel Dis.](#) 2014 Sep;20(9):1496-501.

Bjerrum JT, Nielsen OH, Riis LB, Pittet V, Mueller C, Rogler G, Olsen J. *Transcriptional Analysis of Left-sided Colitis, Pancolitis, and Ulcerative Colitis-associated Dysplasia.* [Inflamm Bowel Dis.](#) 2014 Dec;20(12):2340-52.

Herzog D, Fournier N, Buehr P, Koller R, Rueger V, Heyland K, Nydegger A, Spalinger J, Schibli S, Braegger C, On behalf of the Swiss IBD Cohort Study Group. *Early-onset Crohn's disease is a risk factor for smaller final height.* [Eur J Gastroenterol Hepatol.](#) 2014 Nov;26(11):1234-9.

Herzog D, Buehr P, Koller R, Rueger V, Heyland K, Nydegger A, Spalinger J, Schibli S, Braegger CP, Swiss IBD Cohort Study Group. *Gender Differences in Paediatric Patients of the Swiss Inflammatory Bowel Disease Cohort Study.* [Pediatr Gastroenterol Hepatol Nutr.](#) 2014 Sep;17(3):147-54.

Hiroz P, Vavricka SR, Fournier N, Safroneeva E, Pittet V, Rogler G, Schoepfer AM; Swiss Inflammatory Bowel Disease Cohort Study Group. *Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.* [Scand J Gastroenterol.](#) 2014 Oct;49(10):1207-18.

Hubbard-Lucey VM, Shono Y, Maurer K, West ML, Singer NV, Ziegler CG, Lezcano C, Motta AC, Schmid K, Levi SM, Murphy GF, Liu C, Winkler JD, Amaravadi RK, Rogler G, Dickinson AM, Holler E, van den Brink MR, Cadwell K. *Autophagy gene atg16l1 prevents lethal T cell alloreactivity mediated by dendritic cells.* [Immunity.](#) 2014 Oct 16;41(4):579-91.

Leucht K, Fischbeck A, Caj M, Liebisch G, Hartlieb E, Benes P, Fried M, Humpf HU, Rogler G, Hausmann M. *Sphingomyelin and phosphatidylcholine contrarily affect the induction of apoptosis in intestinal epithelial cells.* [Mol Nutr Food Res.](#) 2014 Apr;58(4):782-98.

Maillard MH, Bortolotti M, Vader J-P, Mottet C, Schoepfer A, Gonvers J-J, Burnand B, Froehlich F, Michetti P, Pittet V, The Swiss IBD Cohort Study Group. *Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis.* [J Crohns Colitis.](#) 2014 Aug;8(8):825-34.

Manser C N, MD, MSc, Frei P, MD, Grandinetti T, Biedermann L, MD, Mwinyi J, MD, MSc, PhD, Vavricka SR, Schoepfer A, MD, Fried M, MD, and Rogler G, MD, PhD, the investigators of the Swiss IBD Cohort Study. *Risk Factors for Repetitive Ileocolic Resection in Patients with Crohn's Disease: Results of an Observational Cohort Study.* [Inflamm Bowel Dis.](#) 2014 Sep;20(9):1548-54.

Mecklenburg I, Reznik D, Fasler-Kan E, Drewe J, Beglinger C, Hruz P, On behalf of the Swiss IBD Cohort Study Group. *Serum hepcidin concentrations correlate with ferritin in patients with inflammatory bowel disease.* [J Crohns Colitis.](#) 2014 Nov;8(11):1392-7.

Pittet V, Rogler G, Mottet C, Froehlich F, Michetti P, de Saussure P, Burnand B, Vader JP & the Swiss IBD cohort study group. *Patient's information-seeking activity is associated with treatment compliance in inflammatory bowel disease patients.* [Scand J Gastroenterol.](#) 2014 Jun;49(6):662-73.

Protic M, Seibold F, Schoepfer A, Radojicic Z, Juillerat P, Bojic D, Mwinyi J, Mottet C, Jojic N, Beglinger C, Vavricka S, Rogler G, Frei P. *The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients.* [J Crohns Colitis.](#) 2014 Nov;8(11):1427-37.

Rogler G. *Crohn's disease : Fistulising disease--a problem shared is a problem halved?* [Nat Rev Gastroenterol Hepatol.](#) 2014 Oct;11(10):581-3.

Rogler D, Fournier N, Pittet V, Bühr P, Heyland K, Friedt M, Koller R, Rueger V, Herzog D, Nydegger A, Schächli M, Schibli S, Spalinger J, Rogler G, Braegger C, Swiss IBD Cohort Study Group. *Coping is excellent in Swiss children with inflammatory bowel disease: Results from the Swiss IBD cohort study.* [J Crohns Colitis.](#) 2014 May;8(5):409-20.

Rogler G. *New therapeutic avenues for treatment of fibrosis: can we learn from other diseases?* [Dig Dis.](#) 2014;32 Suppl 1:39-49.

Roth S, Spalinger MR, Müller I, Lang S, Rogler G, Scharl M. *Bilberry-derived anthocyanins prevent IFN- $\gamma$ -induced pro-inflammatory signalling and cytokine secretion in human THP-1 monocytic cells.* [Digestion.](#) 2014;90(3):179-89.

Schaffer T, Schoepfer AB, Seibold F; Swiss IBD Cohort Study Group. *Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity.* [J Crohns Colitis.](#) 2014 Sep;8(9):1125-32.

Scharl M, Rogler G. *Pathophysiology of fistula formation in Crohn's disease.* [World J Gastrointest Pathophysiol.](#) 2014 Aug 15;5(3):205-12.

Schoepfer AM, Bortolotti M, Pittet V, Mottet C, Gonvers JJ, Reich O, Fournier V, Vader JP, Burnand B, Michetti P, Froehlich F. *The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease.* [Aliment Pharmacol Ther.](#) 2014 Oct;40(8):930-7.

Seibold F, Fournier N, Beglinger C, Mottet C, Pittet V, Rogler G; Swiss IBD cohort study group. *Topical therapy is underused in patients with ulcerative colitis.* [J Crohns Colitis.](#) 2014 Jan;8(1):56-63.

Vavricka SR, Radivojevic S, Manser CN, Frei P, Burri E, Fried M, Schoepfer A, Peyrin-Biroulet L, Michetti P, Rogler G, Biedermann L. *Addressing current treatment challenges in Crohn's disease in real life: A physician's survey.* [Dig Liver Dis.](#) 2014 Dec;46(12):1066-71.

Vavricka SR, Schoepfer AM, Scharl M, Rogler G. *Steroid Use in Crohn's Disease.* [Drugs.](#) 2014 Mar;74(3):313-24.

Vavricka SR, Rogler G, Maetzler S, Misselwitz B, Safroneeva E, Frei P, Manser CN, Biedermann L, Fried M, Higgins P, Wojtal KA, Schoepfer AM. *High altitude journeys and flights are associated with an increased risk of flares in inflammatory bowel disease patients.* [J Crohns Colitis.](#) 2014 Mar;8(3):191-9.

Violi NV, Schoepfer AM, Fournier N, Guiu B, Bize P, Denys A for the Swiss Inflammatory Bowel Disease Cohort Study Group. *Prevalence and Clinical Importance of Mesenteric Venous Thrombosis in the Swiss Inflammatory Bowel Disease Cohort.* [AJR Am J Roentgenol.](#) 2014 Jul;203(1):62-9.

Werner H, Landolt MA, Buehr P, Koller R, Nydegger A, Spalinger J, Heyland K, Schibli S, Braegger CP, Swiss IBD Cohort Study Group. *Validation of the IMPACT-III quality of life questionnaire in Swiss children with inflammatory bowel disease.* [J Crohns Colitis.](#) 2014 Jul;8(7):641-8.

Wojtal KA, Cee A, Lang S, Götze O, Frühauf H, Geier A, Pastor-Anglada M, Torres-Torronteras J, Martí R, Fried M, Lutz TA, Maggiorini M, Gassmann M, Rogler G, Vavricka SR. *Down-regulation of duodenal SLC transporters and activation of pro-inflammatory signaling constitute the early response to high altitude in humans.* [Am J Physiol Gastrointest Liver Physiol.](#) 2014 Oct 1;307(7):G673-88.

## 2013

Biedermann L, Kerl K, Rogler G, Hofbauer GF. *Drug-induced erythema nodosum after the administration of certolizumab in Crohn's disease.* [Inflamm Bowel Dis.](#) 2013 Jan;19(1):E4-6.

Biedermann L, Mwinyi J, Scharl M, Frei P, Zeitz J, Kullak-Ublick GA, Vavricka SR, Fried M, Weber A, Humpf HU, Pescke S, Jetter A, Krammer G, Rogler G. *Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis - An open pilot study.* [J Crohns Colitis.](#) 2013 May;7(4):271-9.

Frei SM, Hemsley C, Pesch T, Lang S, Weber A, Jehle E, Rühl A, Fried M, Rogler G, Scharl M. *The role for dickkopf-homolog-1 in the pathogenesis of Crohn's disease-associated fistulae.* [PLoS One.](#) 2013 Nov 8;8(11):e78882.

Frei SM, Pesch T, Lang S, Weber A, Jehle E, Vavricka SR, Fried M, Rogler G, Scharl M. *A Role for Tumor Necrosis Factor and Bacterial Antigens in the Pathogenesis of Crohn's Disease-Associated Fistulae.* [Inflamm Bowel Dis.](#) 2013 Dec;19(13):2878-87.

Hausmann M, Rechsteiner T, Caj M, Benden C, Fried M, Boehler A, Rogler G. *A new heterotopic transplant animal model of intestinal fibrosis.* [Inflamm Bowel Dis.](#) 2013 Oct;19(11):2302-14.

Herzog D, Landolt MA, Buehr P, Heyland K, Rogler D, Koller R, Rueger V, Pittet V, Nydegger A, Spalinger J, Schäppi M, Schibli S, Braegger CP, and the Swiss IBD Cohort Study Group. *Low prevalence of behavioural and emotional problems among Swiss paediatric patients with inflammatory bowel disease.* [Arch Dis Child.](#) 2013 Jan;98(1):16-9.

Manser CN, Paul M, Rogler G, Held L, Frei T. *Heat waves, incidence of infectious gastroenteritis, and relapse rates of inflammatory bowel disease: a retrospective controlled observational study.* [Am J Gastroenterol.](#) 2013 Sep;108(9):1480-5.

Morón B, Spalinger M, Kasper S, Atrott K, Frey-Wagner I, Fried M, McCole DF, Rogler G, Scharl M. *Activation of protein tyrosine phosphatase non-receptor type 2 by spermidine exerts anti-inflammatory effects in human THP-1 monocytes and in a mouse model of acute colitis.* [PLoS One.](#) 2013 Sep 9;8(9):e73703.

Nielsen OH, Bjerrum JT, Herfarth H, Rogler G. *Recent advances using immuno-modulators for inflammatory bowel disease.* [J Clin Pharmacol.](#) 2013 Jun;53(6):575-88.

Pittet V, Froehlich F, Maillard M, Mottet C, Gonvers JJ, Felley C, Vader JP, Burnand B, Michetti P, Schoepfer A; EPACK-II update panellists. *When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel.* [J Crohns Colitis.](#) 2013 Nov;7(10):820-6.

Pittet V, Rogler G, Michetti P, Fournier N, Vader JP, Schoepfer A, Mottet C, Burnand B, Froehlich F, and for the Swiss Inflammatory Bowel Disease Cohort Study Group. *Penetrating or structuring diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease.* [Digestion.](#) 2013;87(3):212-21.

Rogler G. *Top-down or step-up treatment in Crohn's disease?* [Dig Dis.](#) 2013;31(1):83-90.

Rogler G, Vavricka S, Schoepfer A, Lakatos PL. *Mucosal healing and deep remission: What does it mean?* [World J Gastroenterol.](#) 2013 Nov 21;19(43):7552-60.

Schaffer T, Flogerzi B, Schoepfer AM, Seibold F, Müller S. *Increased titers of anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients with reduced H-ficolin levels but normal MASP-2 activity.* [J Crohns Colitis.](#) 2013 Feb;7(1):e1-10.

Scharl M, Frei S, Pesch T, Kellermeier S, Arikkat J, Frei P, Fried M, Weber A, Jehle E, Ruhl A, Rogler G. *Interleukin-13 and transforming growth factor beta synergise in the pathogenesis of human intestinal fistulae.* [Gut.](#) 2013 Jan;62(1):63-72.

Scharl M, Vavricka SR, Rogler G. *Review: New anti-cytokines for IBD: what is in the pipeline?* [Curr Drug Targets.](#) 2013 Nov;14(12):1405-20.

Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, Schmidt C, Trummler M, Pittet V, Vavricka SR. *Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.* [Inflamm Bowel Dis.](#) 2013 Feb;19(2):332-41.

Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V, Michetti P, Rogler G, Vavricka SR, Biroulet P. *Diagnostic delay in Crohn's Disease is associated with a complicated disease course and increased operation rate.* [Am J Gastroenterol.](#) 2013 Nov;108(11):1744-53; quiz 1754.

Siebert U, Wurm J, Gothe RM, Arvandi M, Vavricka SR, von Känel R, Bègré S, Sulz MC, Meyenberger C, Sagmeister M; the Swiss IBD Cohort Study Group. *Predictors of Temporary and Permanent Work Disability in Patients with Inflammatory Bowel Disease: Results of the Swiss Inflammatory Bowel Disease Cohort Study.* [Inflamm Bowel Dis.](#) 2013 Mar-Apr;19(4):847-55.

Spalinger MR, Lang S, Weber A, Frei P, Fried M, Rogler G, Scharl M. *Loss of Protein Tyrosine Phosphatase Non-Receptor Type 22 Regulates Interferon-γ-Induced Signaling in Human Monocytes.* [Gastroenterology.](#) 2013 May;144(5):978-988.

Spalinger MR, Lang S, Vavricka SR, Fried M, Rogler G, Scharl M. *Protein Tyrosine Phosphatase Non-Receptor Type 22 modulates NOD2-induced cytokine release and autophagy.* [PLoS One.](#) 2013 Aug 26;8(8):e72384.

Sulz MC, Siebert U, Arvandi M, Gothe RM, Wurm J, von Känel R, Vavricka SR, Meyenberger C, Sagmeister M; Swiss IBD Cohort Study Group. *Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease: Results from the Swiss Inflammatory Bowel Disease Cohort Study.* [Eur J Gastroenterol Hepatol.](#) 2013 Jul;25(7):790-7.

Vavricka SR, Manser CN, Hediger S, Vögelin M, Scharl M, Biedermann L, Rogler G, Seibold F, Sanderink R, Attin T, Schoepfer A, Fried M, Rogler G, Frei P. *Periodontitis and gingivitis in inflammatory bowel disease: a case-control study.* [Inflamm Bowel Dis.](#) 2013 Dec;19(13):2768-77.

Vavricka SR, Schoepfer AM, Safroneeva E, Rogler G, Schwenkglens, M, Achermann R. *A shift from oral to intravenous iron supplementation therapy is observed over time in a large Swiss cohort of patients with inflammatory bowel disease.* [Inflamm Bowel Dis.](#) 2013 Mar-Apr;19(4):840-6.

Wojtal KA, Wolfram L, Frey-Wagner I, Lang S, Scharl M, Vavricka SR, Rogler G. *The effects of vitamin A on cells of innate immunity in vitro.* [Toxicol In Vitro.](#) 2013 Aug;27(5):1525-32.

## 2012

Attinkara R, Mwinyi J, Truninger K, Regula J, Gaj P, Rogler G, Kullak-Ublick GA, Eloranta JJ; Siwss IBD Cohort Study Group. *Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR with inflammatory bowel disease.* [BMC Res Notes.](#) 2012 Aug 28;5:461.

Becker HM, Bertschinger MM, Rogler G. *Microparticles and their impact on intestinal immunity.* [Dig Dis.](#) 2012;30 Suppl 3:47-54.

Biedermann L, Rogler G. *Environmental factors and their impact on the intestinal microbiota: a role for human disease?* [Dig Dis.](#) 2012;30 Suppl 3:20-7.

Biedermann L, Rogler G, Vavricka SR, Seibold F, Seirafi M. *Pregnancy and Breastfeeding in Inflammatory Bowel Disease.* [Digestion.](#) 2012;86 Suppl 1:45-54

Burri E, Beglinger C, Lehmann FS. *Monitoring of Therapy for Inflammatory Bowel Disease.* [Digestion.](#) 2012;86 Suppl 1:1-5.

Cámara RJ, Juillerat P, Pittet V, Schoepfer AM, Begre S, von Känel R, the Swiss Inflammatory Bowel Disease Cohort Study Group. *Quality of life: a potentially useful measure to indicate subclinical flares in Crohn disease.* [Intern Med J.](#) 2012 Jul;42(7):e145-51.

Chevaux JB, Vavricka SR, Rogler G, Lakatos PL, Schoepfer A, Peyrin-Biroulet L. *Mucosal Healing with Anti-TNF Antibodies.* [Digestion.](#) 2012;86 Suppl 1:16-22.

Frei P, Biedermann L, Manser CN, Wilk M, Manz M, Vavricka SR, Rogler G. *Topical Therapies in Inflammatory Bowel Disease.* [Digestion.](#) 2012;86 Suppl 1:36-44.

Girardin M, Manz M, Manser C, Biedermann L, Wanner R, Frei P, Safroneeva E, Mottet C, Rogler G, Schoepfer AM. *First-Line Therapies in Inflammatory Bowel Disease.* [Digestion.](#) 2012;86 Suppl 1:6-10

Lakatos PL, Lakatos L, Kiss LS, Peyrin-Biroulet L, Schoepfer A, Vavricka S. *Treatment of Extraintestinal Manifestations in Inflammatory Bowel Disease.* [Digestion.](#) 2012;86 Suppl 1:28-35

Manz M, Vavricka SR, Wanner R, Lakatos PL, Rogler G, Frei P, Safroneeva E, Schoepfer AM. *Therapy of Steroid-Resistant Inflammatory Bowel Disease.* [Digestion.](#) 2012;86 Suppl 1:11-5.

Rogler G. *Inflammatory bowel disease cancer risk, detection and surveillance.* [Dig Dis.](#) 2012;30 Suppl 2:48-54.

Saurer L, Rihs S, Birrer M, Saxer-Seculic N, Radsak M, Mueller C, The Swiss IBD Cohort Study. *Elevated levels of serum-soluble triggering receptor expressed on myeloid cells-1 in patients with IBD do not correlate with intestinal TREM-1 mRNA expression and endoscopic disease activity.* [J Crohns Colitis.](#) 2012 Oct;6(9):913-23.

Scharl M, Mwinyi J, Fischbeck A, Leucht K, Eloranta JJ, Arikkat J, Pesch T, Kellermeier S, Mair A, Kullak-Ublick GA, Truninger K, Noreen F, Regula J, Gaj P, Pittet V, Mueller C, Hofmann C, Fried M, McCole DF, Rogler G. *Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy.* [Inflamm Bowel Dis.](#) 2012 May;18(5):900-12.

Scharl M, Rogler G. *Inflammatory bowel disease: dysfunction of autophagy?* [Dig Dis.](#) 2012;30 Suppl 3:12-9.

Scharl M, Wojtal KA, Becker HM, Fischbeck A, Frei P, Arikkat J, Pesch T, Kellermeier S, Boone DL, Weber A, Loessner MJ, Vavricka SR, Fried M, McCole DF, Rogler G. *Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells.* [Inflamm Bowel Dis.](#) 2012 Jul;18(7):1287-302.

Schoepfer AM, Safroneeva E, Vavricka SR, Peyrin-Biroulet L, Mottet C. *Treatments in Inflammatory Bowel Disease: Treatment of Fibrostenotic and Fistulizing Crohn's Disease.* [Digestion.](#) 2012;86 Suppl 1:23-7.

Vavricka SR, Rogler G. *Intestinal absorption and vitamin levels: is a new focus needed?* [Dig Dis.](#) 2012;30 Suppl 3:73-80.

Vavricka SR, Bentele N, Scharl M, Rogler G, Zeitz J, Frei P, Straumann A, Binek J, Schoepfer AM, Fried M; Swiss IBDnet and Swiss IBD Cohort Study Group. *Systematic assessment of factors influencing preferences of crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).* [Inflamm Bowel Dis.](#) 2012 Aug;18(8):1523-30.

Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, Mottet C, Braegger CP, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer AM; Swiss IBD Cohort Study Group. *Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease.* [Inflamm Bowel Dis.](#) 2012 Mar;18(3):496-505.

Wojtal KA, Rogler G, Scharl M, Biedermann L, Frei P, Fried M, Weber A, Eloranta JJ, Kullak-Ublick GA, Vavricka SR. *Fc gamma receptor CD64 modulates the inhibitory activity of infliximab.* [PLoS One.](#) 2012;7(8):e43361.

## 2011

Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagace C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Buning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RS, Floyd JA, Florin T, Franchimont D, Franke L, Georges M, Glas J, Glazer NL, Guthery SL, Haritunians T, Hayward NK, Hugot JP, Jobin G, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, McGovern DP, Milla M, Montgomery GW, Morley KI, Mowat C, Ng A, Newman W, Ophoff RA, Papi L, Palmieri O, Peyrin-Biroulet L, Panes J, Phillips A, Prescott NJ, Proctor DD, Roberts R, Russell R, Rutgeerts P, Sanderson J, Sans M, Schumm P, Seibold F, Sharma Y, Simms LA, Seielstad M, Steinhart AH, Targan SR, van den Berg LH, Vatn M, Verspaget H, Walters T, Wijmenga C, Wilson DC, Westra HJ, Xavier RJ, Zhao ZZ, Ponsioen CY, Andersen V, Torkvist L, Gazouli M, Anagnou NP, Karlsen TH, Kupcinskis L, Sventoraityte J, Mansfield JC, Kugathasan S, Silverberg MS, Halfvarson J, Rotter JI, Mathew CG, Griffiths AM, Geary R, Ahmad T, Brant SR, Chamaillard M, Satsangi J, Cho JH, Schreiber S, Daly MJ, Barrett JC, Parkes M, Annes V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, Rioux JD. *Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.* [Nat Genet.](#) 2011 Mar;43(3):246-52.

Braegger CP, Ballabeni P, Rogler D, Vavricka SR, Fried M, Pittet V, Swiss IBD Cohort Study Group. *Epidemiology of inflammatory bowel disease: Is there a shift towards onset at a younger age?* [J Pediatr Gastroenterol Nutr.](#) 2011 Aug;53(2):141-4.

Cámara RJ, Gander ML, Begre S, von Känel R, Swiss Inflammatory Bowel Disease Cohort Study Group. *Post-traumatic stress in Crohn's disease and its association with disease activity.* [Frontline Gastroenterol.](#) 2011 Jan;2(1):2-9.

Cámara RJ, Begre S, von Kanel R, Swiss Inflammatory Bowel Disease Cohort Study Group. *Avoidance and inhibition do not predict nonrespondent bias among patients with inflammatory bowel disease.* [J Epidemiol.](#) 2011;21(1):44-51.

Cámara RJ, Lukas PS, Begre S, Pittet V, von Kanel R; Swiss Inflammatory Bowel Disease Cohort Study Group. *Effects of social support on the clinical course of Crohn's disease.* [Inflamm Bowel Dis.](#) 2011 Jun;17(6):1277-86.

Cámara RJ, Schoepfer AM, Pittet V, Begre S, von Kanel R; Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) Group. *Mood and nonmood components of perceived stress and exacerbation of Crohn's disease.* [Inflamm Bowel Dis.](#) 2011 Nov;17(11):2358-65.

Eloranta JJ, Wenger C, Mwynyi J, Hiller C, Gubler C, Vavricka SR, Fried M, Kullak-Ublick GA, Swiss IBD Cohort Study Group. *Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease.* [Pharmacogenet Genomics.](#) 2011 Sep;21(9):559-64.

Fischbeck A, Leucht K, Frey-Wagner I, Bentz S, Pesch T, Kellermeier S, Krebs M, Fried M, Rogler G, Hausmann M, Humpf H-U. *Sphingomyelin induces cathepsin D mediated apoptosis in intestinal epithelial cells and increases inflammation in DSS colitis.* [Gut.](#) 2011 Jan;60(1):55-65.

Olsen J, Bjerrum JT, Hansen M, Troelsen JT, Pittet V, Müller C, Rogler G, Nielsen OH. *Overexpression of receptors for insulin and epidermal growth factor in dysplastic inflamed correlates with increased cancer risk in patients with ulcerative colitis.* [Gastroenterology.](#) 2011; 140(5 suppl. 1): S-350.

Rivas MA, Beaudoin M, Gardet A, Stevens C, Sharma Y, Zhang CK, Boucher G, Ripke S, Ellinghaus D, Burt N, Fennell T, Kirby A, Latiano A, Goyette P, Green T, Halfvarson J, Haritunians T, Korn JM, Kuruvilla F, Lagace C, Neale B, Lo KS, Schumm P, Torkvist L, National Institute of D, Digestive Kidney Diseases Inflammatory Bowel Disease Genetics C, United Kingdom Inflammatory Bowel Disease Genetics C, International Inflammatory Bowel Disease Genetics C, Dubinsky MC, Brant SR, Silverberg MS, Duerr RH, Altshuler D, Gabriel S, Lettre G, Franke A, D'Amato M, McGovern DP, Cho JH, Rioux JD, Xavier RJ, Daly MJ. *Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease.* [Nat Genet.](#) 2011 Oct 9;43(11):1066-73.



Rogler G. *Red alert' or not? - do we give our inflammatory bowel disease patients the right dietary recommendations?* [Digestion](#). 2011;84(3):236-7.

Rogler G. *Interaction between susceptibility and environment: examples from the digestive tract.* [Dig Dis](#). 2011;29(2):136-43.

Rogler G. *Pathogenesis of strictures in ulcerative colitis: a field to explore.* [Digestion](#). 2011;84(1):10-1.

Scharl M, Frei P, Fried M, Rogler G, Vavricka SR. *Association between Cogan's syndrome and inflammatory bowel disease: a case series.* [J Crohns Colitis](#). 2011 Feb;5(1):64-8.

Scharl M, Geisel S, Vavricka SR, Rogler G. *Dying in yoghurt: the number of living bacteria in probiotic yoghurt decreases under exposure to room temperature.* [Digestion](#). 2011;83(1-2):13-7.

Scharl M, McCole DF, Weber A, Vavricka SR, Frei P, Kellermeier S, Pesch T, Fried M, Rogler G. *Protein tyrosine phosphatase N2 regulates TNFalpha-induced signalling and cytokine secretion in human intestinal epithelial cells.* [Gut](#). 2011 Feb;60(2):189-97.

Scharl M, Weber A, Furst A, Farkas S, Jehle E, Pesch T, Kellermeier S, Fried M, Rogler G. *Potential role for SNAIL family transcription factors in the etiology of Crohn's disease-associated fistulae.* [Inflamm Bowel Dis](#). 2011 Sep;17(9):1907-16.

Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, Rogler G, Schoepfer AM. *Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort.* [Am J Gastroenterol](#). 2011 Jan;106(1):110-9.

Vavricka SR, Schoepfer AM, Bansky G, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Scharl M, Seibold F, Straumann A, Michetti P, Swiss IBDnet. *Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.* [Inflamm Bowel Dis](#). 2011 Jul;17(7):1530-9.

## 2010

Cámara RJ, Begre S, von Kanel R. [The effect of stress-relieving interventions on inflammatory bowel disease: quality assessment of 10 therapeutic studies]. [Z Psychosom Med Psychother](#). 2010;56(2):116-35.

Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lee CW, Blaschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Scharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Buning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Geary R, Glas J, Van Gossom A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libiouille C, Louis E, Mowat C, Newman W, Panes J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhardt AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wildson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersam RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M. *Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.* [Nat Genet](#). 2010 Dec;42(12):1118-25.

Juillerat P, Pittet V, Vader JP, Burnand B, Gonvers JJ, de Saussure P, Mottet C, Seibold F, Rogler G, Sagmeister M, Felley C, Michetti P, Froehlich F, Swiss IBDCSG. *Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness.* [Eur J Gastroenterol Hepatol](#). 2010 Nov;22(11):1352-7.

Mwinyi J, Wenger C, Eloranta JJ, Kullak-Ublick GA. *Glucocorticoid receptor gene haplotype structure and steroid therapy outcome in IBD patients.* [World J Gastroenterol](#). 2010 Aug 21;16(31):3888-96.

Nichita C, Stelle M, Vavricka S, El-Wafa Ali A, Ballabeni P, de Saussure P, Straumann A, Rogler G, Michetti P. *Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease.* [Digestion](#). 2010;81(2):78-85.

Pittet V, Juillerat P, Michetti P, Vader JP, Burnand B, Rogler G, Beglinger C, Seibold F, Mottet C, Felley C, Gonvers JJ, Froehlich F, Swiss IBD Cohort Study Group. *Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort.* [Aliment Pharmacol Ther](#). 2010 Oct;32(8):1007-16.

Schmidt S, Guibal A, Meuwly JY, Michetti P, Felley C, Meuli R, Schnyder P, Denys A. *Acute complications of Crohn's disease: comparison of multidetector-row computed tomographic enterography with magnetic resonance enterography.* [Digestion](#). 2010;82(4):229-38.

Schoepfer AM, Beglinger C, Straumann A, Trummel M, Vavricka SR, Bruegger LE, Seibold F. *Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.* [Am J Gastroenterol](#). 2010 Jan;105(1):162-9.

Schoepfer AM, Vavricka SR, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Seibold F, Straumann A, Michetti P; Swiss IBDnet. *Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.* [Inflamm Bowel Dis.](#) 2010 Jun;16(6):933-8.

Vavricka SR, Rogler G. *Recent advances in the etiology and treatment of Crohn's disease.* [Minerva Gastroenterol Dietol.](#) 2010 Jun;56(2):203-11.

Vavricka SR, Rogler G. *Fistula Treatment: The unresolved challenge.* [Dig Dis.](#) 2010;28(3):556-64.

Voegtlin M, Vavricka SR, Schoepfer AM, Straumann A, Voegtlin J, Rogler G, Ballabeni P, Pittet V, Buser A, Fried M, Beglinger C, Swiss IBD Cohort Study. *Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals.* [J Crohns Colitis.](#) 2010 Dec;4(6):642-8.

## 2009

Binda E, Erhart D, Schenk M, Zufferey C, Renzulli P, Mueller C. *Quantitative isolation of mouse and human intestinal intraepithelial lymphocytes by elutriation centrifugation.* [J Immunol Methods.](#) 2009 May 15;344(1):26-34.

Cámara RJ, Ziegler R, Begre S, Schoepfer AM, von Kanel R, Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) group. *The role of psychological stress in inflammatory bowel disease: quality assessment of methods of 18 prospective studies and suggestions for future research.* [Digestion.](#) 2009;80(2):129-39.

Eloranta JJ, Zair ZM, Hiller C, Hausler S, Stieger B, Kullak-Ublick GA. *Vitamin D3 and its nuclear receptor increase the expression and activity of the human proton-coupled folate transporter.* [Mol Pharmacol.](#) 2009 Nov;76(5):1062-71.

Felley C, Vader JP, Juillerat P, Pittet V, O'Morain C, Panis Y, Vucelic B, Gonvers JJ, Mottet C, Froehlich F, Michetti P; EPACT II Study Group. *Appropriate therapy for fistulizing and fibrostenotic Crohn's disease: Results of a multidisciplinary expert panel - EPACT II.* [J Crohns Colitis.](#) 2009 Dec;3(4):250-6.

Juillerat P, Pittet V, Mottet C, Felley C, Gonvers JJ, Vader JP, Burnand B, Froehlich F, Wolters FL, Stockbrugger RW, Michetti P; EC-IBD Group. *Appropriateness of early management of newly diagnosed Crohn's disease in a European population-based cohort.* [Scand J Gastroenterol.](#) 2010 Dec;45(12):1449-56

Juillerat P, Vader JP, Felley C, Pittet V, Gonvers JJ, Mottet C, Bemelman WA, Lemann M, Oresland T, Michetti P, Froehlich F, Group EPACT II Study Group. *Appropriate maintenance treatment for Crohn's disease: Results of a multidisciplinary international expert panel - EPACT II.* [J Crohns Colitis.](#) 2009 Dec;3(4):241-9.

Lee J, Tattoli I, Wojtal KA, Vavricka SR, Philpott DJ, Girardin SE. *pH-dependent internalization of muramyl peptides from early endosomes enables Nod1 and Nod2 signaling.* [J Biol Chem.](#) 2009 Aug 28;284(35):23818-29.

Manz M, Beglinger C, Vavricka SR. *Fatal invasive pulmonary aspergillosis associated with adalimumab therapy.* [Gut.](#) 2009 Jan;58(1):149.

Michetti P, Stelle M, Juillerat P, Gassull M, Heil FJ, Stange E, Mottet C, Gonvers JJ, Pittet V, Vader JP, Froehlich F, Felley C, the EPACT II Study Group. *Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel-EPACT II.* [J Crohns Colitis.](#) 2009 Dec;3(4):232-40.

Müller S, Rihs S, Schneider JM, Paredes BE, Seibold I, Brunner T, Mueller C. *Soluble TNF-alpha but not transmembrane TNF-alpha sensitizes T cells for enhanced activation-induced cell death.* [Eur J Immunol.](#) 2009 Nov;39(11):3171-80.

Pittet V, Juillerat P, Mottet C, Felley C, Ballabeni P, Burnand B, Michetti P, Vader JP; Swiss IBD Cohort Study Group. *Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS).* [Int J Epidemiol.](#) 2009 Aug;38(4):922-31.

Schoepfer AM, Beglinger C, Straumann A, Trummel M, Renzulli P, Seibold F. *Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes.* [Inflamm Bowel Dis.](#) 2009 Dec;15(12):1851-8.

Schoepfer AM, Flogerzi B, Seibold-Schmid B, Schaffer T, Kun JF, Pittet V, Mueller S, Seibold F. *Low Mannan-binding lectin serum levels are associated with complicated Crohn's disease and reactivity to oligomannan (ASCA).* [Am J Gastroenterol.](#) 2009 Oct;104(10):2508-16

Schoepfer AM, Schaffer T, Mueller S, Flogerzi B, Vassella E, Seibold-Schmid B, Seibold F. *Phenotypic associations of Crohn's disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort.* [Inflamm Bowel Dis.](#) 2009 Sep;15(9):1358-67.

Vavricka SR, Burri E, Beglinger C, Degen L, Manz M. *Serum protein electrophoresis: an underused but very useful test.* [Digestion.](#) 2009;79(4):203-10.

Vavricka SR, Manz M, Burri E. *Trichuris trichiura (whipworm).* [Clin Gastroenterol Hepatol.](#) 2009 Oct;7(10):A16.

Vavricka SR, Rogler G. *Treatment of severe ulcerative colitis: differences in elderly patients?* [Dig Dis.](#) 2009;27(3):315-21.

Vavricka SR, Rogler G. *[Therapy of ulcerative colitis].* [Praxis \(Bern 1994\).](#) 2009 Feb 18;98(4):209-12.

Vavricka SR, Rogler G. *[Treatment of Crohn's disease].* [Praxis \(Bern 1994\).](#) 2009 Jan 21;98(2):77-81.

Vavricka SR, Rogler G. *New insights into the pathogenesis of Crohn's disease: are they relevant for therapeutic options?* [Swiss Med Wkly.](#) 2009 Sep 19;139(37-38):527-34

Wojtal KA, Eloranta JJ, Hruz P, Gutmann H, Drewe J, Staumann A, Beglinger C, Fried M, Kullak-Ublick GA, Vavricka SR. *Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients.* [Drug Metab Dispos.](#) 2009 Sep;37(9):1871-7.

Zeitl J, Mulla Haupt B, Fruehauf H, Rogler G, Vavricka SR. *Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone.* [Hepatology.](#) 2009 Aug;50(2):653-4.

## 2008

Juillerat P, Pittet V, Bulliard JL, Guessous I, Antonino AT, Mottet C, Felley C, Vader JP, Michetti P. *Prevalence of Inflammatory Bowel Disease in the Canton of Vaud (Switzerland). A population-based cohort study.* [J Crohns Colitis.](#) 2008 Jun;2(2):131-41.

Schenk M, Mueller C. *The mucosal immune system at the gastrointestinal barrier.* [Best Pract Res Clin Gastroenterol.](#) 2008;22(3):391-409.

## 2007

Carlson RM, Vavricka SR, Eloranta JJ, Musch MW, Arvans DL, Kles KA, Walsh-Reitz MM, Kullak-Ublick GA, Chang EB. *fMLP induces Hsp27 expression, attenuates NF-kappaB activation, and confers intestinal epithelial cell protection.* [Am J Physiol Gastrointest Liver Physiol.](#) 2007 Apr;292(4):G1070-8.

Felley C, Mottet C, Juillerat P, Pittet V, Froehlich F, Vader John-Paul, Michetti P, Gonvers JJ. *Fistulizing Crohn's Disease.* [Digestion.](#) 2007;76(2):109-12.

Froehlich F, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Gonvers JJ, Michetti P. *Fibrostenotic Crohn's disease.* [Digestion.](#) 2007;76(2):113-5.

Froehlich F, Juillerat P, Pittet V, Felley C, Mottet C, Vader JP, Michetti P, Gonvers JJ. *Maintenance of surgically induced remission of Crohn's disease.* [Digestion.](#) 2007;76(2):130-5.

Gonvers JJ, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Michetti P, Froehlich F. *Maintenance of medically induced remission of Crohn's disease.* [Digestion.](#) 2007;76(2):116-29.

Guessous I, Juillerat P, Pittet V, Froehlich F, Burnand B, Mottet C, Felley C, Michetti P, Vader JP. *Evaluating appropriateness of treatment for Crohn's disease: feasibility of an explicit approach.* [Digestion.](#) 2007;75(1):46-52

Juillerat P, Christen-Zach S, Troillet FX, Gallot-Lavallee S, Pannizzon RG, Michetti P. *Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.* [Dermatology.](#) 2007;215(3):245-51.

Juillerat P, Froehlich F, Felley C, Pittet V, Mottet C, Gonvers JJ, Michetti P, Vader JP. *EPACT II: project and methods.* [Digestion.](#) 2007;76(2):84-91.

Juillerat P, Mottet C, Pittet V, Froehlich F, Felley C, Gonvers JJ, Vader JP, Michetti P. *Extraintestinal manifestations of Crohn's disease.* [Digestion.](#) 2007;76(2):141-8.

Juillerat P, Pittet V, Felley C, Mottet C, Froehlich F, Vader JP, Gonvers JJ, Michetti P. *Drug safety in Crohn's disease therapy.* [Digestion.](#) 2007;76(2):161-8.

Meier Y, Eloranta JJ, Darimont J, Ismail MG, Hiller C, Fried M, Kullak-Ublick GA, Vavricka SR. *Regional distribution of solute carrier mRNA expression along the human intestinal tract.* [Drug Metab Dispos.](#) 2007 Apr;35(4):590-4.

Michetti P, Juillerat P, Mottet C, Pittet V, Gonvers JJ, Vader JP, Froehlich F, Felley C. *Mild-to-moderate active luminal Crohn's disease*. [Digestion](#). 2007;76(2):92-8.

Michetti P, Mottet C, Juillerat P, Pittet V, Felley C, Vader JP, Gonvers JJ, Froehlich F. *Severe and steroid-resistant Crohn's disease*. [Digestion](#). 2007;76(2):99-108.

Mottet C, Juillerat P, Pittet V, Gonvers JJ, Froehlich F, Vader JP, Michetti P, Felley C. *Pregnancy and breastfeeding in patients with Crohn's disease*. [Digestion](#). 2007;76(2):149-60.

Mottet C, Vader JP, Felley C, Froehlich F, Gonvers JJ, Juillerat P, Stockbrugger R, Angelucci E, Seibold F, Michetti P, Pittet V, the EPACT II Study Group. *Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): Results of a multidisciplinary international expert panel-EPACT II*. [Digestion](#). 2007;76(2):149-60.

Mottet C, Juillerat P, Pittet V, Gonvers JJ, Michetti P, Vader JP, Felley C, Froehlich F. *Upper gastrointestinal Crohn's disease*. [Digestion](#). 2007;76(2):136-40.

Schenk M, Bouchon A, Seibold F, Mueller C. *TREM-1--expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases*. [J Clin Invest](#). 2007 Oct;117(10):3097-106.

Seibold F, Boldt AB, Seibold-Schmid B, Schoepfer AM, Flogerzi B, Muller S, Kun JF. *Association of deficiency for mannan-binding lectin with anti-mannan antibodies in Crohn's disease: a family study*. [Inflamm Bowel Dis](#). 2007 Sep;13(9):1077-82.

Vavricka SR, Dirnhofer S, Degen L. *Polyarteritis nodosa mimicking inflammatory bowel disease*. [Clin Gastroenterol Hepatol](#). 2007 Nov;5(11):A22.

## 2006

Frei P, Fried M, Hungerbuhler V, Rammert C, Rousson V, Kullak-Ublick GA. *Analysis of risk factors for low bone mineral density in inflammatory bowel disease*. [Digestion](#). 2006;73(1):40-6.

Ismair MG, Vavricka SR, Kullak-Ublick GA, Fried M, Mengin-Lecreux D, Girardin SE. *hPepT1 selectively transports muramyl dipeptide but not Nod1-activating muramyl peptides*. [Can J Physiol Pharmacol](#). 2006 Dec;84(12):1313-9.

Vader JP, Froehlich F, Juillerat P, Burnand B, Felley C, Gonvers JJ, Mottet C, Pittet V, Dubois RW, Wietlisbach V, Michetti P. *Appropriate treatment for Crohn's disease: methodology and summary results of a multidisciplinary international expert panel approach-EPACT*. [Digestion](#). 2006;73(4):237-48.